KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation & Amortization (CF): 2016-2024

Historic Depreciation & Amortization (CF) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $236.2 million.

  • Amneal Pharmaceuticals' Depreciation & Amortization (CF) fell 8.29% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.5 million, marking a year-over-year increase of 5.94%. This contributed to the annual value of $236.2 million for FY2024, which is 2.96% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' Depreciation & Amortization (CF) stood at $236.2 million, which was up 2.96% from $229.4 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $240.2 million for FY2022, and its period low was $229.4 million during FY2023.
  • For the 3-year period, Amneal Pharmaceuticals' Depreciation & Amortization (CF) averaged around $235.3 million, with its median value being $236.2 million (2024).
  • Per our database at Business Quant, Amneal Pharmaceuticals' Depreciation & Amortization (CF) climbed by 13.58% in 2020 and then declined by 4.49% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Depreciation & Amortization (CF) stood at $235.4 million in 2020, then declined by 0.84% to $233.4 million in 2021, then climbed by 2.90% to $240.2 million in 2022, then decreased by 4.49% to $229.4 million in 2023, then rose by 2.96% to $236.2 million in 2024.